东莞证券给予福元医药增持评级：Q2业绩增速有所承压

Group 1 - The core viewpoint of the report is that Dongguan Securities has given a "buy" rating to Fuyuan Pharmaceutical (601089.SH) with a latest price of 30.8 yuan [2] - The reasons for the rating include a slowdown in the company's Q2 performance growth and an acceleration in the promotion of research and development innovation [2]